Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
PredxBio
AddedFeb 16, 2024
UpdatedJun 18, 2026
PredxBio

PredxBio

Seed

PredxBio: Advancing precision pathology with AI for optimized clinical trials and personalized therapy.

HQ
Pittsburgh, PA, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

PredxBio was founded with the mission to revolutionize precision pathology by integrating unbiased spatial analytics and explainable AI. The company's vision is to enhance personalized medicine, particularly in the field of immunotherapy for cancer patients. PredxBio offers solutions that empower clinicians and researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows.

Notable affiliated individuals and investors have not been disclosed publicly. Key achievements include the development of platforms that reveal intermediate cell types, their functional states, and intercellular communications. PredxBio's impact is significant in the realm of precision medicine, providing novel insights that are crucial for improving patient outcomes and advancing the field of personalized therapy.

PredxBio - Similar Companies

SpIntellx logo

SpIntellx

predxbio.com

BioAI Health logo

BioAI Health

bioaihealth.com

Path BioAnalytics logo

Path BioAnalytics

HI-Bio logo

HI-Bio

hibio.com

Predictive Oncology logo

Predictive Oncology

Endpoint Health logo

Endpoint Health

Prenosis logo

Prenosis

prenosis.com

bioSyntagma logo

bioSyntagma

biosyntagma.com

Pbs-Bio logo

Pbs-Bio

Predictive Biosciences logo

Predictive Biosciences

OncoPrecision logo

OncoPrecision

oncoprecision.bio

Predictive Health Diagnostics Company logo

Predictive Health Diagnostics Company

Singularity.AI logo

Singularity.AI

singularity.ai

Precision Theranostics logo

Precision Theranostics

Precede Biosciences logo

Precede Biosciences

precede.bio

PredxBio - Quick Facts

Who are PredxBio's competitors?

Companies similar to PredxBio include SpIntellx, BioAI Health, Path BioAnalytics and HI-Bio.

When was PredxBio founded?

PredxBio was founded in 2017.

Where is PredxBio's headquarters located?

PredxBio's headquarters is located in Pittsburgh, PA, US.

When was PredxBio's last funding round?

PredxBio's most recent funding round was for $601.3k (USD) in August 2023.

How much has PredxBio raised to-date?

As of Aug 17, 2023, PredxBio has raised a total of $1.1M (USD).

How many employees does PredxBio have?

PredxBio has 13 employees as of Feb 5, 2024.

PredxBio - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Diagnostics
  • Precision Pathology
Tags
  • Biotech
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software